Sat, Apr 19, 2014, 12:53 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • rommell_james rommell_james Oct 27, 2013 5:22 PM Flag

    Anyone give a guess on this

    Why has Inovio held the HIV infected trial back so long?? Serious inquirys only.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • For the same reason that nothing has advanced to Phase 3 in 34 years.
      Inovio is peddling failed "technology".
      It failed in 199 when Inovio used the alias, Genetronics.
      It failed for Chrontech this year and nearly put them out of business.
      INO has NOTHING.

    • The data is available. They are presenting it at various meetings. Not sure I understand the question. The publication for the uninfected patients is out. As far as why the publication for the infected patients with the vaccine, they submitted both around the same time. They may have tried submitting the infected patients trial to a higher impact scientific journal than the uninfected one. The results in uninfected patients was published in Journal of Infectious Disease. Impact factor is about 6-7. They may have tried to send the infected patients HIV vaccine trial to a higher impact journal like Science Translational Medicine (where the VGX3100 HPV trial was published, Impact Factor about 11). If that's the case, it usually takes a lot longer to get it through the editors and the scientific review panel and sometimes they require more studies to be performed. Doing more studies in patients is tough, especially HIV infected patients who have received a vaccine.

      At any rate, this vaccine that they published on and did this study on will be shelved no matter what (they will not pursue Pennvax G, because they are pursuing Pennvax GP, so it is a moot point at this point. Pennvax G was aimed to get only cytotoxic T cell responses. Pennvax GP gets both T cell and B cell responses.

    • They will probably piggy back the PENNVAX GP launch. Which is also supposed to happen this year. GP is more robust so they will have momentum.

    • KR's probably got the most insight on this. We were both talking about it 4Q of 2012, when the original results were supposed to be out. Maybe the ORR is 100%; last I heard it was 89%.

      SENTIMENT: VERY STRONG BUY

 
INO
2.52-0.15(-5.62%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Rayonier Inc.
NYSEThu, Apr 17, 2014 4:03 PM EDT